CORONA, CA, May 18, 2009 (MARKETWIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, today announced the promotion of Patricia L.
Eisenhaur, 46, to Vice President, Investor Relations and Corporate
"Since joining the company, Patty has played a key role in building
our investor relations function and raising Watson's visibility with
shareholders, analysts and the media," said Paul Bisaro, Watson's
President and Chief Executive Officer. "She brings unique qualities
and a wealth of experience in a wide variety of communications which
will serve us well as we position ourselves for further growth."
Ms. Eisenhaur joined Watson in 2001 as Director, Investor Relations
and most recently was Executive Director Investor Relations. Prior to
her tenure at Watson, Ms. Eisenhaur spent five years at ALZA
Corporation (a Johnson & Johnson Company), in various investor
relations positions of increasing responsibility. Ms. Eisenhaur will
be transitioning to the company's Morristown, NJ location.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is a global leader in the development
and distribution of pharmaceuticals with a broad portfolio of generic
products and a specialized portfolio of brand pharmaceuticals focused
on Urology, Women's Health and Nephrology/Medical.
For press release and other company information, visit Watson
Pharmaceuticals' Web site at http://www.watson.com.
Watson Pharmaceuticals, Inc.
SOURCE: Watson Pharmaceuticals